Replies to post #736468 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

How can the technology not work for other types of cancers? Did you happen to read about the following trial and the publication? Three tough pediatric sarcomas. 30% patients who had either metastasized or recurrent cancer remain cancer free five years after the treatment. More importantly, tumor lysate was prepared from the tumor tissue obtained via biopsy needle. It should not be called DCVax-L. But without doubt the pulsing technology that makes DC swallow tumor lysate, digest it and present hundreds of tumor-associated peptides on the surface of dendritic cells is the same the one adopted in DCVax-L.

Also recall what Les said in Big Biz Show "patients with 15 types of tumors were treated with DCVax-L, most of them blockbuster drugs".

I don't see why you think it would take years. First, did 10Q say that the outcome measure of tumor shrinkage will be adopted and results will be available in months? Second, see the following figure. Was the number of blue dots (cancer cells) significantly reduced after the 2nd shots of the vaccine? That's basically two or three weeks after the initiation of the treatment.


Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma
https://clinicaltrials.gov/study/NCT00923351

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas
https://aacrjournals.org/clincancerres/article/22/13/3182/79179/Adjuvant-Immunotherapy-to-Improve-Outcome-in-High

[Hopeforthefuture3]

Gary, UCLS has been using immune stimulants such as poly-iclc in at least some of their trials for quite some time. This is from a paper from 2011 with Prins as primary author:

The concomitant administration of 5% imiquimod or poly ICLC with DC vaccination was also found to be safe and did not result in any additional toxicity or adverse events. To our knowledge, this is the first report of the use of TLR agonists in conjunction with DC vaccination strategies in brain tumor patients. Because TLR agonists were used only in patients in the booster phase, it is unclear whether or to what extent the addition of the TLR agonists contributed to the potential efficacy and overall survival of these patients. Furthermore, imiquimod and poly-ICLC are two different biological agents, targeting different TLRs. Imiquimod activates TLR-7, while poly-ICLC activates TLR-3, but both induce pro-inflammatory cytokine secretion. These complexities make it somewhat difficult to determine how these innate immune modifiers actually contributed to our study endpoints. Nevertheless, this current study establishes the safety of these TLR agonists in conjunction with glioma lysate-loaded DC, and further Phase II studies directly comparing these TLR agonists at the time of initial vaccination (not only in the booster phase) are currently underway.

https://pmc.ncbi.nlm.nih.gov/articles/PMC3071163/